KRAS and neoplasm: It was recently suggested that amplification of ERBB2 comprises another resistance mechanism [12], [13], and that acquired resistance is conferred by mutation of EGFR itself [14] or results from expansion of tumor subclones with mutated or amplified KRAS[15], [16].